FOLH1 and metastatic neoplasm: While newer imaging techniques like prostate-specific membrane antigen positron emission tomography (PSMA PET) and whole-body magnetic resonance imaging (MRI) are not yet included in the definition of metastatic disease burden, they hold promise for further refining patient selection in the future.